Allogeneic cell therapy market seen reaching $1.97 billion by 2030

The allogeneic cell therapy market is projected to grow from $1.2 billion in 2025 to $1.97 billion by 2030, according to The Business Research Company. Demand is being lifted by chronic disease prevalence, broader clinical use and advances in stem cell and immune cell engineering.

Why it matters: - Allogeneic cell therapy is moving from a niche treatment area toward broader use in cancer, genetic conditions and autoimmune disorders. - The market outlook points to steady demand for donor-derived therapies as chronic disease cases rise and healthcare systems look for new treatment options.

What happened: - The Business Research Company published its Global Market Report 2026 for allogeneic cell therapy on Oct. 30, 2026. - The report estimates the market at $1.2 billion in 2025 and $1.34 billion in 2026. - The report projects the market will reach $1.97 billion by 2030. - The forecast implies a 10.2% compound annual growth rate from 2026 to 2030.

The details: - Allogeneic cell therapy uses cells from a donor to treat a different recipient. - The therapies are designed to restore or replace damaged tissues, regulate immune responses and treat disease. - The report links near-term growth to limited availability of products, more early-stage clinical trials, rising hematological disorder prevalence, higher hospital adoption and reliance on donor cell banks. - The report links forecast-period growth to advances in stem cell and immune cell engineering, broader dermatology use, more manufacturing investment, hospital-biotech collaborations and automated cell processing. - Key trends include more focus on stem cell therapies, T-cell therapies, NK cell therapies, induced pluripotent stem cell-based treatments, personalized cell therapies and stricter regulatory and safety standards. - The report says rising chronic disease prevalence is a major growth driver for the market. - NCBI data released in January 2023 projects the number of people age 50 and older with one or more chronic diseases will nearly double by 2050, from 71.52 million in 2020 to 142.66 million. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The report also covers Western and Eastern Europe, South East Asia, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and the full report online: the sample request and the full market report.

Between the lines: - The market outlook suggests donor-derived cell therapies are gaining traction as commercialization improves and clinical use widens. - North America’s lead reflects stronger healthcare infrastructure and research activity, while Asia-Pacific’s growth points to expanding investment and patient demand.

What's next: - The market is expected to keep expanding through 2030 if engineering advances, manufacturing scale-up and regulatory progress continue. - Wider adoption of automated cell processing and personalized cell therapies could shape how quickly the market grows.

The bottom line: - Allogeneic cell therapy is projected to remain a fast-growing market, with the strongest gains likely to come from broader clinical applications and continued technology development.